Abstract
A new combination of reagent (ZnCl2/TBAB) system has been developed for the preparation of dihydropyrimidinones by using aldehyde, acetoacetic ester and urea or thiourea. These improved reaction condition allow the preparation of a wide variety of substituted dihydropyrimidinones in high yields and purity under mild reaction conditions. Some of the dihydropyrimidinones were showed moderate in vitro cytotoxic activity against U937, Colo205, A549 and THP-1 human cancer cell lines. Some of the compounds have been found promising anticancer activity when compared standard drug etoposide.
Keywords: Biginelli reaction, ZnCl2/TBAB catalyst, Dihydropyrimidinones, One pot synthesis, MTT assay, Cytotoxicity.
Letters in Drug Design & Discovery
Title:Synthesis and Cytotoxic Evaluation for Some New Dihydropyrimidinone Derivatives for Anticancer Activity
Volume: 10 Issue: 8
Author(s): Onteddu. Surendranatha Reddy, Ch. Venkata Suryanarayana, N. Sharmila, G. V. Ramana, V. Anuradha and B. Hari Babu
Affiliation:
Keywords: Biginelli reaction, ZnCl2/TBAB catalyst, Dihydropyrimidinones, One pot synthesis, MTT assay, Cytotoxicity.
Abstract: A new combination of reagent (ZnCl2/TBAB) system has been developed for the preparation of dihydropyrimidinones by using aldehyde, acetoacetic ester and urea or thiourea. These improved reaction condition allow the preparation of a wide variety of substituted dihydropyrimidinones in high yields and purity under mild reaction conditions. Some of the dihydropyrimidinones were showed moderate in vitro cytotoxic activity against U937, Colo205, A549 and THP-1 human cancer cell lines. Some of the compounds have been found promising anticancer activity when compared standard drug etoposide.
Export Options
About this article
Cite this article as:
Reddy Surendranatha Onteddu., Suryanarayana Venkata Ch., Sharmila N., Ramana V. G., Anuradha V. and Babu Hari B., Synthesis and Cytotoxic Evaluation for Some New Dihydropyrimidinone Derivatives for Anticancer Activity, Letters in Drug Design & Discovery 2013; 10 (8) . https://dx.doi.org/10.2174/15701808113109990007
DOI https://dx.doi.org/10.2174/15701808113109990007 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy
Current Medicinal Chemistry Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis
Current Cancer Therapy Reviews Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Cellular Toxicity and Apoptosis Studies in Osteocarcinoma Cells, a Comparison of 177Lu-EDTMP and Lu-EDTMP
Current Radiopharmaceuticals The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Novel Virally Targeted Therapies of EBV-Associated Tumors
Current Cancer Drug Targets A Bioinorganic Perspective on Matrix Metalloproteinase Inhibition
Current Topics in Medicinal Chemistry AAV-Mediated Gene Supply for Treatment of Degenerative and Neovascular Retinal Diseases
Current Gene Therapy To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Noscapine-loaded PLA Nanoparticles: Systematic Study of Effect of Formulation and Process Variables on Particle Size, Drug Loading and Entrapment Efficiency
Pharmaceutical Nanotechnology Recurrent Left Atrial Low-grade Malignant Inflammatory Myofibroblastic Tumor Characterized by Cardiovascular Magnetic Resonance
Current Medical Imaging Designed Multiple Ligands for Cancer Therapy
Current Medicinal Chemistry Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry The Roles of Sox Family Genes in Sarcoma
Current Drug Targets